GRIFOLS reported EUR326M in Selling and Administration Expenses for its fiscal quarter ending in September of 2026.





Selling And Administration Expenses Change Date
Alcon AG USD 964M 82M Jun/2026
Almirall -29.5M 4.72M Jun/2026
Amadeus IT EUR 497.5M 206.6M Mar/2025
Amarin USD 18.97M 1.03M Dec/2025
argenx SE USD 598M 181M Sep/2026
AstraZeneca USD 4.07B 1.73B Sep/2026
Bayer EUR 4.02B 53M Sep/2026
Cie Automotive EUR 315.66M 28.06M Dec/2024
Demant DKK 7.09B 1B Jun/2026
Ence Energia y Celulosa EUR 29.1M 2M Sep/2024
Essilor EUR 5.75B 139M Jun/2026
Ferrovial EUR 906M 52M Dec/2024
Fresenius EUR 823M 63M Sep/2026
Fresenius Medical Care EUR 744M 7.99M Sep/2026
Genmab DKK 205M 39M Jun/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
GRIFOLS EUR 326M 37M Sep/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Inditex EUR 2.51B 7.98B Jan/2025
Lakefront Biotherapeutics EUR 22.5M 13M Jun/2026
Merck EUR 1.58B 11M Sep/2026
Novartis USD 3.08B 163M Sep/2026
Philips EUR 1.17B 33M Sep/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.31B 325M Sep/2026
Smith & Nephew USD 1.45B 29M Jun/2026
UCB EUR 1.47B 193M Dec/2025
Viscofan EUR 72.59M 4.52M Mar/2025